Associate Director, Precision Medicine & Companion Diagnostics

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.

As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is offering a highly visible opportunity for talented and motivated individual to join our Precision Medicine Companion Diagnostics team as an Associate Director, Companion Diagnostics within the Translational Medicine function, which supports CDx development across RevMed portfolio. Through both scientific and cross-functional leadership, individual is to implement global diagnostic strategies to enable and support the global development and commercialization of medically differentiated therapies.

The successful candidate will have the opportunity to work in a fast-paced, highly collaborative environment and will be a key member of multidisciplinary development project teams. Required Skills, Experience and Education: Lead the development and implementation of diagnostic strategies through registration and launch for individual clinical studies and/or molecule program. Direct the development, outsourcing and validation of clinically applicable in vitro diagnostic assays through the development lifecycle of molecules, including design, implement and oversee diagnostic testing and registration strategy and timely communication with key internal and external stakeholders.

g. NGS-based tissue and ctDNA assays, PCR, immunohistochemistry), evaluating their scientific basis and clinical applicability, the validation status and any technical or statistical issues related to the proposed companion diagnostic assay. Oversee implementation of clinical trial assays at CRO laboratories for centralized testing supporting clinical trials.

Monitors all scope or changes in study are timely implemented, including the development of the work order, costs and agreements. Lead joint development teams between RevMed and Dx partners to ensure cross-functional alignment of overarching development, regulatory and commercialization strategy, successful fit for purpose CDx development and that co-development timelines are met. Serve as subject matter expert in diagnostic regulation and support the interactions with global health authorities regarding companion diagnostics development and submissions.

Preferred Skills: Highly experienced biomarker or diagnostics professional (MS and/or PhD) with a minimum of 7-10 years of relevant industry experience with expertise in oncology biomarker and/or companion diagnostic development. High level of initiative and ability to work independently with business awareness, hands on experience in IVD development processes and global in vitro diagnostic regulatory aspects related to companion diagnostic development. Experience with biomarker application in clinical trials and awareness of the challenges of implementing diagnostic technologies in the clinical setting.

Experience with health authority interactions and regulatory submissions for pharmaceutical and/or in vitro diagnostics development globally. Excellent leadership skills including motivation and influencing without authority.